Table of Contents

NPDUIS: How can it be used to promote optimal drug therapy?

Perspective

Origins of NPDUIS

Early concerns about NPDUIS

Question 1: Is the name NPDUIS adequate or appropriate

Question 2: Will analytic reports prepared by NPDUIS be predicatble and routine, or will they promote new methods and unearth new knowledge about drug prescribing and pharmaceutical outcomes?

Secondary deliverable as described October 7 by Michael Decter

Question 3: Why would we choose to create 4 new national entities to address different elements of optimal drug use?

The real requirement

Question 4: How can an initiative like NPDUIS best contribute to the enhancement of a national capacity for pharmaceutical evaluation?

Accountabilities

Question 5: Shouldn't Canadian academic expertise in drug evaluation have been more closely involved in the NPDUIS planning process before now?

Question 6: What are some of the policy questions NPDUIS should try to address?

Central policy question: How do we obtain the best possible pharmaceutical outcomes at affordable cost?

Question 7: How can NPDUIS be used to promote optimal drug utilization in Canada?

Presentation Author

Stuart MacLeod, MD, PhD, FRCPC, Professor, Clinical Epidemiology and Biostatistics, Pediatrics and Medicine, McMaster University
( http://www.fhs.mcmaster.ca )

PMPRB Email

pmprb@pmprb-cepmb.gc.ca

PMPRB Symposium 2002, List of Presentations

http://www.pmprb.com/symposium2002/present-e.html